Avoro Capital Advisors LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Avoro Capital Advisors LLC reported 46 stock positions worth $8.6 billion. Its top holding was United Therapeutics (UTHR) at 7.7% of the portfolio, followed by Apellis Pharmaceuticals (APLS, 7.6%) and Ascendis Pharma A/S (ASND, 7.0%). Compared with Q4 2023, it opened 11 new positions, sold out of 7, added to 15 and reduced 3. The biggest buy was a new position in Viking Therapeutics (VKTX) and the biggest sale an exit from Mirati Therapeutics (MRTX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001633313
- Portfolio Value
- $8.6B (Q1 2024)
- SEC Filing
- 0001104659-24-061613 ↗ filed May 15, 2024
Holdings Value
Holdings 46 stocks · $8.6B
| UTHR United Therapeutics Corp. | 7.66% | 2,858,888 | $656.7M | No change |
| APLS Apellis Pharmaceuticals Inc. | 7.62% | 11,111,111 | $653.1M | No change |
| ASND Ascendis Pharma A/S | 6.99% | 3,966,666 | $599.6M | Add +5.6% |
| SRPT Sarepta Therapeutics Inc. | 6.56% | 4,344,444 | $562.4M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 6.06% | 1,944,444 | $519.2M | Add +2.9% |
| ARGX Argenx SE - ADR | 5.69% | 1,238,467 | $487.6M | Add +0.3% |
| KRYS Krystal Biotech Inc. | 5.30% | 2,555,555 | $454.7M | Reduce -0.4% |
| XBI SS SPDR S&P Biotech ETF | 4.76% | 4,300,000 | $408.0M | Reduce -3.3% |
| BMRN Biomarin Pharmaceutical Inc. | 4.45% | 4,365,000 | $381.2M | Add +1.5% |
| FOLD Amicus Therapeutics Inc. | 3.76% | 27,400,000 | $322.8M | No change |
| CERE Cerevel Therapeutics Holding | 3.73% | 7,555,555 | $319.4M | No change |
| VKTX Viking Therapeutics Inc. | 3.43% | 3,590,000 | $294.4M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 2.85% | 8,555,555 | $244.7M | Add +657.1% |
| XENE Xenon Pharmaceuticals Inc. | 2.85% | 5,666,666 | $243.9M | No change |
| ALPN Alpine Immune Sciences Inc. | 2.67% | 5,775,000 | $228.9M | New |
| VERA Vera Therapeutics Inc. | 2.65% | 5,265,000 | $227.0M | New |
| IOVA Iovance Biotherapeutics Inc. | 2.02% | 11,700,000 | $173.4M | Add +74.6% |
| ITCI Intra-Cellular Therapies Inc. | 2.00% | 2,475,000 | $171.3M | Add +9.7% |
| KYMR Kymera Therapeutics Inc. | 1.82% | 3,888,888 | $156.3M | Add +3.0% |
| RNAM Avidity Biosciences Inc. | 1.73% | 5,825,000 | $148.7M | Add +132.1% |
| MLTX Moonlake Immunotherapeutics | 1.51% | 2,580,000 | $129.6M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 1.17% | 4,222,222 | $100.5M | No change |
| MGNX Macrogenics Inc. | 1.06% | 6,150,000 | $90.5M | New |
| KURA Kura Oncology Inc. | 0.96% | 3,850,000 | $82.1M | Add +29.2% |
| AUTL Autolus Therapeutics PLC | 0.92% | 12,345,678 | $78.8M | New |
| SYRE Spyre Therapeutics Inc. | 0.81% | 1,839,138 | $69.8M | No change |
| SLNO Soleno Therapeutics Inc. | 0.81% | 1,625,000 | $69.5M | Add +107.0% |
| BCRX Biocryst Pharmaceuticals Inc. | 0.77% | 13,050,000 | $66.3M | No change |
| OCUL Ocular Therapeutix Inc. | 0.76% | 7,148,936 | $65.1M | New |
| TSHA Taysha Gene Therapies Inc. | 0.62% | 18,650,000 | $53.5M | Add +328.2% |
| TRML Tourmaline Bio Inc. | 0.59% | 2,222,222 | $50.9M | Add +155.9% |
| ROIV Roivant Sciences Ltd. | 0.57% | 4,651,162 | $49.0M | No change |
| ALNY Alnylam Pharmaceuticals Inc. | 0.52% | 300,000 | $44.8M | Reduce -73.0% |
| MNKD Mannkind Corp. | 0.48% | 9,000,000 | $40.8M | No change |
| MRUS Merus NV | 0.47% | 888,888 | $40.0M | No change |
| PCVX Vaxcyte Inc. | 0.46% | 575,000 | $39.3M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 0.45% | 830,000 | $38.8M | Add +137.1% |
| MRNS Marinus Pharmaceuticals Inc. | 0.44% | 4,140,607 | $37.4M | Add +31.4% |
| RCKT Rocket Pharmaceuticals Inc. | 0.40% | 1,260,900 | $34.0M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 0.37% | 4,535,000 | $32.0M | No change |
| CGON CG Oncology Inc. | 0.36% | 700,000 | $30.7M | New |
| CRSP Crispr Therapeutics AG | 0.33% | 419,580 | $28.6M | New |
| VRCA Verrica Pharmaceuticals Inc. | 0.28% | 3,999,999 | $23.7M | No change |
| KYTX Kyverna Therapeutics Inc. | 0.14% | 475,000 | $11.8M | New |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 0.08% | 2,849,402 | $6.7M | No change |
| ADVM Adverum Biotechnologies Inc. | 0.07% | 416,666 | $5.9M | New |
Portfolio Sells Q4 2023 → Q1 2024
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −3.97 |
| CBAY Cymabay Therapeutics Inc. | Sold out | 0.00% | −3.63 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -73.0% | 0.52% | −2.41 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −1.31 |
| XBI SS SPDR S&P Biotech ETF | Reduce -3.3% | 4.76% | −0.72 |
| KRTX Karuna Therapeutics Inc. | Sold out | 0.00% | −0.55 |
| IMGN Immunogen Inc. | Sold out | 0.00% | −0.36 |
| FENC Fennec Pharmaceuticals Inc. | Sold out | 0.00% | −0.19 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −0.18 |
| KRYS Krystal Biotech Inc. | Reduce -0.4% | 5.30% | +0.91 |
Portfolio Buys Q4 2023 → Q1 2024
| VKTX Viking Therapeutics Inc. | New | 3.43% | +3.43 |
| ALPN Alpine Immune Sciences Inc. | New | 2.67% | +2.67 |
| VERA Vera Therapeutics Inc. | New | 2.65% | +2.65 |
| ARWR Arrowhead Pharmaceuticals Inc. | Add +657.1% | 2.85% | +2.38 |
| RNAM Avidity Biosciences Inc. | Add +132.1% | 1.73% | +1.42 |
| IOVA Iovance Biotherapeutics Inc. | Add +74.6% | 2.02% | +1.27 |
| MGNX Macrogenics Inc. | New | 1.06% | +1.06 |
| AUTL Autolus Therapeutics PLC | New | 0.92% | +0.92 |
| OCUL Ocular Therapeutix Inc. | New | 0.76% | +0.76 |
| TSHA Taysha Gene Therapies Inc. | Add +328.2% | 0.62% | +0.52 |
| KYMR Kymera Therapeutics Inc. | Add +3.0% | 1.82% | +0.50 |
| ASND Ascendis Pharma A/S | Add +5.6% | 6.99% | +0.46 |
| PCVX Vaxcyte Inc. | New | 0.46% | +0.46 |
| SLNO Soleno Therapeutics Inc. | Add +107.0% | 0.81% | +0.37 |
| KURA Kura Oncology Inc. | Add +29.2% | 0.96% | +0.37 |
| CGON CG Oncology Inc. | New | 0.36% | +0.36 |
| CRSP Crispr Therapeutics AG | New | 0.33% | +0.33 |
| TRML Tourmaline Bio Inc. | Add +155.9% | 0.59% | +0.28 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +137.1% | 0.45% | +0.22 |
| KYTX Kyverna Therapeutics Inc. | New | 0.14% | +0.14 |
| ADVM Adverum Biotechnologies Inc. | New | 0.07% | +0.07 |
| MDGL Madrigal Pharmaceuticals Inc. | Add +2.9% | 6.06% | +0.02 |
| MRNS Marinus Pharmaceuticals Inc. | Add +31.4% | 0.44% | −0.04 |
| ITCI Intra-Cellular Therapies Inc. | Add +9.7% | 2.00% | −0.23 |
| ARGX Argenx SE - ADR | Add +0.3% | 5.69% | −0.80 |
| BMRN Biomarin Pharmaceutical Inc. | Add +1.5% | 4.45% | −1.28 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $11.1B | UTHR, ASND, KRYS, MDGL, ARGX |
| Q1 2026 | 30 | $10.2B | UTHR, ASND, MDGL, KRYS, ARGX |
| Q4 2025Amended | 33 | $10.2B | UTHR, ASND, MDGL, ARGX, KRYS |
| Q3 2025 | 30 | $7.7B | ASND, UTHR, MDGL, ARGX, KRYS |
| Q2 2025 | 30 | $5.7B | ASND, UTHR, ARGX, MDGL, KRYS |
| Q1 2025 | 33 | $6.4B | UTHR, ASND, ARGX, MDGL, KRYS |
| Q4 2024 | 39 | $7.1B | UTHR, ARGX, ASND, MDGL, KRYS |
| Q3 2024 | 35 | $6.9B | UTHR, ASND, ARGX, KRYS, MDGL |
| Q2 2024 | 41 | $7.5B | UTHR, MDGL, ASND, ARGX, SRPT |
| Q1 2024 | 46 | $8.6B | UTHR, APLS, ASND, SRPT, MDGL |